BriaCell Therapeutics Corp. Quarterly Net Cash Provided by (Used in) Financing Activities in USD for Q3 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
BriaCell Therapeutics Corp. annual/quarterly Net Cash Provided by (Used in) Financing Activities history and growth rate for Q3 2022.
  • BriaCell Therapeutics Corp. Net Cash Provided by (Used in) Financing Activities for the quarter ending October 31, 2022 was -$47.3K.
  • BriaCell Therapeutics Corp. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $3.95M.
  • BriaCell Therapeutics Corp. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$3.74M, a 106% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2022 -$47.3K Aug 1, 2022 Oct 31, 2022 10-Q 2023-12-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.